Internal personnel at Leiyi went all in and bought heavily after the stock price plummeted.

Regulatory data shows that internal personnel at Eli Lilly company bought heavily after the stock price plummeted. Last Thursday, the company's stock price fell by about 14% due to the mid-term data of the oral GLP-1 candidate drug orforglipron in Phase III trial ATTAIN-1 falling short of expectations, marking the largest single-day drop in over twenty years. However, after the stock price plummeted, CEO David Ricks purchased approximately 1600 shares at an average price of $644.77, and Chief Scientific Officer Dan Skovronsky increased his holdings by 1000 shares at $634 per share. Directors Gabrielle Sulzberger and Erik Frywald collectively bought 1700 shares, driving up the internal ownership percentage by several percentage points.